August 12, 2022 05:55 AM EDTUpdated 06:45 AM

As Covid program advances, Enanta's new CMO says it's not 'limited to antivirals'; With all eyes on Gilead-partnered cancer drugs, Arcus brings medical chief on board

Alex Hoffman

Senior Editor

Kathy Wong

Editor

Kyle LaHucik

Senior Reporter

Expect some pipeline adjustments at Enanta Pharmaceuticals in the coming years, because new CMO Scott Rottinghaus thinks the antiviral biotech can …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

As Covid program advances, Enanta's new CMO says it's not 'limited to antivirals'; With all eyes on Gilead-partnered cancer drugs, Arcus brings medical chief on board

Alex Hoffman

Senior Editor

Kathy Wong

Editor

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

As Covid pro­gram ad­vances, Enan­ta's new CMO says it's not 'lim­it­ed to an­tivi­ral­s'; With all eyes on Gilead-part­nered can­cer drugs, Ar­cus brings med­ical chief on board

Senior Editor

Editor

Senior Reporter

Sign up to read this article for free.

As Covid program advances, Enanta's new CMO says it's not 'limited to antivirals'; With all eyes on Gilead-partnered cancer drugs, Arcus brings medical chief on board